Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01292993 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01292993 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT01292993, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of LX4211 and metformin on each other when given at the same time as single doses to healthy human subjects.
Interventions
- DRUG 400 mg LX4211
- DRUG 1000 mg metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01292993
The ClinicalTrials.gov registry entry for NCT01292993 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 400 mg LX4211 is the first listed.
NCT01292993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01292993 about?
NCT01292993 is a clinical study titled "A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects". The purpose of this study is to determine the effects of LX4211 and metformin on each other when given at the same time as single doses to healthy human subjects.
What is the current status of trial NCT01292993?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-02.
What interventions are being tested in trial NCT01292993?
The interventions under investigation include: 400 mg LX4211 (DRUG), 1000 mg metformin (DRUG).
Who is sponsoring clinical trial NCT01292993?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.